
Whereas topical therapies are the main stay in the first phases of psoriasis, systemic therapies become much more upfront, and dermatologists realise that psoriasis is, to a large extent, a systemic disease. It is the implementation of new biologics (three anti IL-17 molecules and three anti IL-23 molecules) together with the development of small molecules that revolutionises the treatment of psoriasis. On the same page, dermatologist realise the importance of early diagnosis of comorbidities of psoriasis.
The shift from short-term intervention to long-term, safe control was also reflected in the various presentations. Drug survival has become an important outcome measure. Further, biomarkers to predict treatment responsiveness of individual patients and to predict which patients are more likely to develop comorbidities are important research targets for the future.
This congress, at a crossroads from classical systemics and first-generation biologics to a future with innovative highly selective biologics and small molecules, was an outstanding opportunity to get a comprehensive insight into pathogenesis-based treatment of psoriasis. The congress gave a glimpse in the future of other inflammatory skin diseases with the promise of pathogenesis-based treatment for these diseases as well. The future for inflammatory skin diseases is bright.
Prof. dr Peter C.M. van de Kerkhof
Senior professor of dermatologyRadboud University Nijmegen Medical CentreThe Netherlands
Biography
Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was board member of various international societies. Current interests are: pathogenesis and development of biomarkers for psoriasis; real clinical practise research; and personalised medicine.
Conflict of Interest Statement
Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma, Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant. Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.
Posted on
Previous Article
« Treatment goals in psoriasis Next Article
Atopic dermatitis and psoriasis: on a spectrum? »
« Treatment goals in psoriasis Next Article
Atopic dermatitis and psoriasis: on a spectrum? »
Table of Contents: SPIN 2019
Featured articles
Letter from the Editor
Aetiology: Triggers and Risk Factors
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in Therapy
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Novel Considerations
Granulomatous rosacea: exploratory histological markers
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Small molecules, apremilast, and TYK2
Related Articles
August 6, 2020
Psoriasis therapy for children and pregnancies

June 21, 2019
Atopic dermatitis and psoriasis: on a spectrum?
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy